Current sort has key articles at the top. Click on "Article Date" to sort by date, click on specific "tag" to view all articles in that category.
Title | |
---|---|
Orphan drug designation spurs trials for cannabidiol in Dravet syndrome [1] 03/21/2014 |
In a survey [2] and other anecdotal reports, parents of children with drug-refractory epilepsy syndromes have reported successful treatment with cannabidiol-enriched marijuana. But little high-quality evidence is available about the efficacy and safety of cannabidiol in patients with Dravet, Lennox-Gastaux, and other pediatric epilepsy syndromes, as shown by a recent Cochrane Collaboration review of four randomized trials totaling 48 patients with epilepsy that found no adverse effects with 200-300 mg daily over short periods but did not report on the efficacy of the drug. Charlotte's Web [3], Dravet syndrome [4], Orphan Study [5] |
Links
[1] http://www.rethinkpot.org/orphan-drug-designation-spurs-trials-cannabidiol-dravet-syndrome
[2] http://www.ncbi.nlm.nih.gov/pubmed/24237632
[3] http://www.rethinkpot.org/tags/charlottes-web
[4] http://www.rethinkpot.org/tags/dravet-syndrome
[5] http://www.rethinkpot.org/tags/orphan-study